Anti-angiogenic active immunotherapy: a new approach to cancer treatment

Cancer Immunol Immunother. 2008 Aug;57(8):1105-14. doi: 10.1007/s00262-008-0452-2. Epub 2008 Jan 24.

Abstract

Tumor angiogenesis plays an important role in tumor growth, aggression and metastasis. Many molecules have been demonstrated as positive regulators of angiogenesis, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and others. In recent years, significant progress has been made in the research on anti-angiogenic strategies for tumor therapies. In this review, anti-angiogenic active immunotherapies for tumors based on vaccination with xenogeneic homologous molecules and non-xenogeneic homologous molecules are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cancer Vaccines / therapeutic use*
  • Epidermal Growth Factor / antagonists & inhibitors
  • Fibroblast Growth Factors / antagonists & inhibitors
  • Humans
  • Immunotherapy*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / immunology*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Cancer Vaccines
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factors
  • Epidermal Growth Factor